At present, recanalization of occluded blood vessels through thrombolysis or thrombectomy with such drugs as tissue plasminogen activator (tPA) is an effective clinical treatment for ischemic stroke approved by the US Food and Drug Administration (FDA) to improve the functional prognosis after acute ischemic stroke [2, 3]. The gene discussed is PLAT; the disease is ischemic stroke.